Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pituitary Neoplasms 3Nelson Syndrome 2Prostatic Neoplasms 1Pituitary ACTH Hypersecretion 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Meningioma 1Carcinoma, Intraductal, Noninfiltrating 1Adrenocortical Hyperfunction 1ACTH Syndrome, Ectopic 1

Interventions

Docetaxel 56Prednisone 36enzalutamide 25Leuprolide 24Magnetic Resonance Spectroscopy 19Abiraterone Acetate 19bicalutamide 17Radiotherapy 15Goserelin 15abiraterone 12acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11olaparib 9Androgen Antagonists 9gallium 68 PSMA-11 8cabazitaxel 8Radiotherapy, Intensity-Modulated 8Metformin 8Ketoconazole 8Gonadotropin-Releasing Hormone 8Cyclophosphamide 8apalutamide 7Doxorubicin 7luprolide acetate gel depot 6cabozantinib 6Radiosurgery 6Estramustine 6Dexamethasone 6Calcitriol 6Biopsy 6pembrolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Prostatic Neoplasms × pasireotide × Clear all
NCT01313559 2025-04-30

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Thomas Jefferson University

Phase 2 Terminated
6 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡